Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 108 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00024089Phase 2
• SU006668 in Treating Patients With Advanced Solid TumorsStatus unknownNCT00024063Phase 1
• Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue SarcomaCompletedNCT00023725Phase 1/2
• Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00023699Phase 2
• Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic LeukemiaCompletedNCT00022737Phase 3
• Phase II/III Study of Anti-VEGF in Neovascular AMDCompletedNCT00021736Phase 2/3
• Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryCompletedNCT00020709Phase 3
• ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseCompletedNCT00016991Phase 2
• ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and NeckCompletedNCT00015964Phase 2
• ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney CancerCompletedNCT00014183Phase 2
• Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00014170Phase 2
• S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00014144Phase 2
• ZD 1839 in Treating Patients With Metastatic Kidney CancerCompletedNCT00012337Phase 2
• Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaCompletedNCT00010049Phase 1/2
• SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous TreatmentTerminatedNCT00009919Phase 2
• Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorTerminatedNCT00009906Phase 3
• STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisCompletedNCT00006475Phase 2
• SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCompletedNCT00006361Phase 2
• STI571 in Treating Patients With Recurrent or Refractory Soft Tissue SarcomaCompletedNCT00006357Phase 1/2
• SU5416 in Treating Children With Recurrent or Progressive Brain TumorsTerminatedNCT00006247Phase 1
• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaCompletedNCT00006053Phase 2
• STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00006052Phase 2
• SU5416 in Treating Patients With Malignant MesotheliomaCompletedNCT00006014Phase 2
• SU5416 in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT00006013Phase 2
• SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTerminatedNCT00006003Phase 2
• SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerTerminatedNCT00006001Phase 2
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentCompletedNCT00005931Phase 2
• SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue SarcomasCompletedNCT00005862Phase 2
• Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate CancerWithdrawnNCT00005827Phase 1
• SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast CancerCompletedNCT00005822Phase 1
• SU5416 and Irinotecan in Treating Patients With Advanced Colorectal CancerCompletedNCT00005818Phase 1/2
• SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and NeckCompletedNCT00005647Phase 1
• SU5416 in Treating Patients With Advanced Solid TumorsCompletedNCT00005642Phase 1
• SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00005042Phase 2
• STI571 in Treating Patients With Recurrent LeukemiaCompletedNCT00004932Phase 1
• SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation TherapyCompletedNCT00004868Phase 1/2
• BIBX 1382 in Treating Patients With Solid TumorsSuspendedNCT00003980Phase 1
• SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00003720Phase 1
• Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First RemissionCompletedNCT00002514Phase 3
• Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002226Not applicable
• A Pharmacokinetic Study of Genistein, a Tyrosine Kinase InhibitorCompletedNCT00001696Phase 1
• CVD Risk and Health in Postmenopausal Phytoestrogen UsersCompletedNCT00000613Phase 2

← Tyrosine Kinase Inhibitors overview